Library
Rilmazolam is a triazolobenzodiazepine and the principal active metabolite of rilmazafone, a prodrug sold under the brand name Rhythmy (リスミー) in Japan and approved there for the treatment of insomnia and as a pre-anesthetic agent. Rilmazolam itself has never been independently developed or approved for medical use in any country.
Also known as: 8-chloro-6-(2-chlorophenyl)-N,N-dimethyl-4H-[1,2,4]triazolo[1,5-a][1,4]benzodiazepine-2-carboxamide
No route information available yet.
Check interactions before mixing substances, pay attention to dose spacing and hydration, and treat all dosage guidance as approximate rather than guaranteed safe.
Substance data is aggregated from the following public harm-reduction and reference sources.
This static page is intended as a readable non-JS and prerender-friendly library export.
Open the interactive DrugsPRO app for search, saved items, interactions, and deeper harm reduction tools.
Get the PRO test kit. The simple, quick and reliable drug checking test kit. Visit https://protestkit.eu
